ClinicalTrials.gg
CompletedNCT00735709Updated Dec 18, 2013Results posted

Efficacy Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder

A Phase 3 interventional study of Vortioxetine and Placebo in Major Depressive Disorder, sponsored by Takeda. Completed at 50 sites in 15 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2013-12-18.

Sponsored by Takeda · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
560
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 54 studies testing vortioxetine in Depressive Disorder, Major — 1 open to participants now, 1 under way, 1 of them phase 3. Vortioxetine · Depressive Disorder, Major.

Enrollment
17th of 54
560 · median 413
Started
2008
with 5 others
Phase 3
31 of 54
1 open now
Registered
7th of 54
by date
Lead sponsor
17 of 54
Takeda

Among the 54 studies testing vortioxetine in Depressive Disorder, Major, this one is the 17th largest by enrollment, is one of 6 that started in 2008, is one of 31 in phase 3, and was the 7th registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

1 of the 54 studies testing vortioxetine in Depressive Disorder, Major is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About vortioxetine

Vortioxetine: first FDA approval 2013 (TRINTELLIX), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies testing vortioxetine in Depressive Disorder, Major, or all of them as a file.
02

Study summary

The purpose of this study is to determine the effectiveness and safety of vortioxetine, once daily (QD), in patients with Major Depressive Disorder.

Read the detailed description

The drug that was tested in this study is called vortioxetine. Vortioxetine is being tested to treat depression in adults who have major depressive disorder (MDD). This study looked at MDD relief in people who took varying dosages of vortioxetine.

The study enrolled 560 patients. Participants were randomly assigned (by chance, like flipping a coin) to one of the four treatment groups-which remained undisclosed to the patient and study doctor during the study (unless there was an urgent medical need):

  • Vortioxetine 1 mg
  • Vortioxetine 5 mg
  • Vortioxetine 10 mg
  • Placebo (dummy inactive pill) - this was a capsule that looked like the study drug but had no active ingredient.

All participants were asked to take one capsule at the same time each day throughout the study.

This multi-centre trial was conducted in Europe, Asia, Australia, and South Africa. The overall time to participate in this study was up to 14 weeks. Participants made 7 visits to the clinic, and were contacted by telephone 4 weeks after the last dose of study drug for a follow-up assessment.

03

Conditions studied

  • Major Depressive Disorder

Keywords

  • Depression
  • Depressive Disorder
  • Mood Disorder
  • Mental Disorder
  • Melancholia, Involutional
  • Paraphrenia, Involutional
  • Drug Therapy
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has a primary diagnosis of major depressive episode according to the , Fourth Edition, Text Revision (DSM-IV-TR) criteria.
  • The reported duration of the current major depressive episode is at least 3 months.
  • Has a Montgomery Åsberg Depression Rating Scale (MADRS) total score ≥26.
  • A male or a female of who is sexually active agrees to use adequate from Screening throughout the duration of the study and for 1 month after the last dose of study medication.

Exclusion criteria

Exclusion Criteria:

  • Has 1 or more the following:

    • Any current psychiatric disorder other than major depressive disorder as defined in the .
    • Current or past history of: manic or hypomanic episode, schizophrenia or any other psychotic disorder, including major depression with psychotic features, mental retardation, organic mental disorders, or mental disorders due to a general medical condition as defined in the DSM-IV-TR.
    • Any substance disorder (except nicotine and caffeine) within the previous 6 months as defined in the DSM-IV-TR. (must have negative urine drug screen prior to Baseline).
    • Presence or history of a neurological disorder (including epilepsy).
    • Neurodegenerative disorder (Alzheimer disease, Parkinson disease, multiple sclerosis, Huntington disease, etc).
  • Has a significant risk of suicide according to the investigator's opinion or has a score ≥5 on item 10 (suicidal thoughts) of the Montgomery Åsberg Depression Rating Scale, or has made a suicide attempt in the previous 6 months.
  • Currently receiving formal cognitive or behavioral therapy, systematic psychotherapy, or plans to initiate such therapy during the study.
  • Has a clinically significant unstable illness.
  • Has previously failed to respond to adequate treatment with selective serotonin reuptake inhibitors and/or serotonin-norepinephrine reuptake inhibitors.
  • Has received electroconvulsive therapy within 6 months prior to Screening.
  • Has an , aspartate aminotransferase, or total level > 1.5 times the .
  • Has a serum creatinine of > 1.5 × upper limit of normal.
  • Has a previous history of cancer that had been in remission for less than 5 years.
  • Has thyroid stimulating hormone value outside the normal range.
  • Has an abnormal .
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
560 participants (actual)

Study arms

  • Experimental
    Vortioxetine 1 mg

    Vortioxetine 1 mg, encapsulated tablets, orally, once daily for up 8 weeks.

    Drug: Vortioxetine

  • Experimental
    Vortioxetine 5 mg

    Vortioxetine 5 mg, encapsulated tablets, orally, once daily for up 8 weeks.

    Drug: Vortioxetine

  • Experimental
    Vortioxetine 10 mg

    Vortioxetine 10 mg, encapsulated tablets, orally, once daily for up 8 weeks.

    Drug: Vortioxetine

  • Placebo comparator
    Placebo

    Vortioxetine placebo-matching capsules, orally, once daily for up to 8 weeks.

    Drug: Placebo

Interventions

  • Encapsulated immediate-release vortioxetine tablets

    Also known as: Lu AA21004, Brintellix®

  • DrugPlacebo

    Vortioxetine placebo-matching capsules

06

What researchers measure

Primary outcomes

  1. Change From Baseline in the 24-item Hamilton Depression Scale Total Score At Week 8

    The 24-item Hamilton Depression Scale (HAM-D24) is a clinician-rated 24-item scale for assessing the severity of depression symptoms. The scores for each item range from 0 to 4 or 0 to 2, where 0 represents no symptoms. The rating is based on the past 7 days prior to the time of assessment. The total score range is from 0 to 74 where a higher score indicates a greater depressive state. Least squares (LS) means are from a mixed model for repeated measurements (MMRM) with Baseline-by-week, center, week, and week-by-treatment as factors in the analysis.

    Time frame: Baseline to Week 8

Secondary outcomes

  1. Change From Baseline in Sheehan Disability Scale (SDS) Total Score at Week 8

    The Sheehan Disability Scale assesses functional impairment in 3 domains: work/school, social life or leisure activities, and home life or family responsibilities. The participant rates the extent to which each aspect is impaired on a 10-point visual analog scale, from 0 (not at all) to 10 (extremely). The 3 scores are added together to calculate the total score, which ranges from 0 to 30, with higher scores indicating more impairment. LS means are from a mixed model for repeated measurements (MMRM) with Baseline-by-week, center, week, and week-by-treatment as factors in the analysis.

    Time frame: Baseline to Week 8

  2. Clinical Global Impression Scale-Global Improvement at Week 8

    The Clinical Global Impression - Global Improvement scale assesses the participant's improvement (or worsening) as assessed by the clinician relative to Baseline on a 7-point scale: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse. LS means are from a mixed model for repeated measurements (MMRM) with Baseline-by-week, center, week, and week-by-treatment as factors in the analysis.

    Time frame: Baseline to Week 8

  3. Percentage of Responders in HAM-D24 Total Score at Week 8

    A responder is defined as a participant with a ≥50% decrease from Baseline in HAM-D24 total score. The HAM-D24 is a clinician-rated 24-item scale for assessing the severity of depression symptoms. The scores for each item range from 0 to 4 or 0 to 2, where 0 represents no symptoms. The rating is based on the past 7 days prior to the time of assessment. The total score ranges from 0 to 74, where a higher score indicates a greater depressive state.

    Time frame: Baseline and Week 8

  4. Change From Baseline in HAM-D24 Total Score at Week 8 in Participants With Baseline HAM-A Score ≥20

    The HAM-D24 is a clinician-rated 24-item scale for assessing the severity of depression symptoms. The scores for each item range from 0 to 4 or 0 to 2, where 0 represents no symptoms. The rating is based on the past 7 days prior to the time of assessment. The total score ranges from 0 to 74 where a higher score indicates a greater depressive state. The Hamilton Anxiety Scale (HAM-A) is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total scores range from 0 (symptoms absent) to 56 (severe symptoms). LS means are from a mixed model for repeated measurements (MMRM) with Baseline-by-week, center, week, and week-by-treatment as factors in the analysis.

    Time frame: Baseline to Week 8

  5. Percentage of Participants in MADRS Remission at Week 8

    Remission is defined as a participant with a Montgomery Åsberg Depression Rating Scale (MADRS) total score ≤10. The MADRS is a depression rating scale consisting of 10 items, each rated 0 to 6. The 10 items represent the core symptoms of depressive illness. The overall score ranges from 0 (symptoms absent) to 60 (severe depression). Decrease in the total score or on individual items indicates improvement.

    Time frame: Week 8

  6. Change From Baseline in the 24-item Hamilton Depression Scale Total Score at Other Weeks Assessed

    The HAM-D24 is a clinician-rated 24-item scale for assessing the severity of depression symptoms. The scores for each item range from 0 to 4 or 0 to 2, where 0 represents no symptoms. The rating is based on the past 7 days prior to the time of assessment. The total score range is from 0 to 74 where a higher score indicates a greater depressive state. LS means are from a mixed model for repeated measurements (MMRM) with Baseline-by-week, center, week, and week-by-treatment as factors in the analysis.

    Time frame: Baseline and Weeks 1, 2, 4 and 6

  7. Change From Baseline in Sheehan Disability Scale (SDS) Total Score at Other Weeks Assessed

    The Sheehan Disability Scale assesses functional impairment in 3 domains: work/school, social life or leisure activities, and home life or family responsibilities. The participant rates the extent to which each aspect is impaired on a 10-point visual analog scale, from 0 (not at all) to 10 (extremely). The 3 scores are added together to calculate the total score, which ranges from 0 to 30, with higher scores indicating more impairment. LS means are from a mixed model for repeated measurements (MMRM) with Baseline-by-week, center, week, and week-by-treatment as factors in the analysis.

    Time frame: Baseline and Weeks 1, 2 and 6

  8. Clinical Global Impression Scale-Global Improvement at Other Weeks Assessed

    The Clinical Global Impression - global improvement assesses the participant's improvement (or worsening) as assessed by the clinician relative to Baseline on a 7-point scale: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse. LS means are from a mixed model for repeated measurements (MMRM) with Baseline-by-week, center, week, and week-by-treatment as factors in the analysis.

    Time frame: Baseline and Weeks 1, 2, 4 and 6

  9. Percentage of Responders in HAM-D24 Total Score at Other Weeks Assessed

    A responder is defined as a participant with a ≥50% decrease from Baseline in HAM-D24 total score. The HAM-D24 is a clinician-rated 24-item scale for assessing the severity of depression symptoms. The scores for each item range from 0 to 4 or 0 to 2, where 0 represents no symptoms. The rating is based on the past 7 days prior to the time of assessment. The total score ranges from 0 to 74, where a higher score indicates a greater depressive state.

    Time frame: Baseline and Weeks 1, 2, 4 and 6

  10. Change From Baseline in HAM-D24 Total Score at Other Weeks Assessed in Participants With a Baseline HAM-A Score ≥20

    The HAM-D24 is a clinician-rated 24-item scale for assessing the severity of depression symptoms. The scores for each item range from 0 to 4 or 0 to 2, where 0 represents no symptoms. The rating is based on the past 7 days prior to the time of assessment. The total score range from 0 to 74 where a higher score indicates a greater depressive state. The Hamilton Anxiety Scale (HAM-A) is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total scores range from 0 (symptoms absent) to 56 (symptoms severe). LS means are from a mixed model for repeated measurements (MMRM) with Baseline-by-week, center, week, and week-by-treatment as factors in the analysis.

    Time frame: Baseline and Weeks 1, 2, 4 and 6

  11. Percentage of Participants in MADRS Remission at Other Weeks Assessed

    Remission is defined as a participant with a Montgomery Åsberg Depression Rating Scale (MADRS) total score ≤10. The MADRS is a depression rating scale consisting of 10 items, each rated 0 to 6. The 10 items represent the core symptoms of depressive illness. The overall score ranges from 0 (symptoms absent) to 60 (severe depression). Decrease in the total score or on individual items indicates improvement.

    Time frame: Weeks 1, 2, 4 and 6

  12. Percentage of Participants With a Sustained Response in HAM-D24 Total Score

    A sustained response is defined as a ≥20% decrease from Baseline in HAM-D24 total score obtained at Week 1 and sustained through Week 7 and at least 50% decrease from Baseline at Week 8.

    Time frame: From Baseline through Week 8

  13. Change From Baseline in Montgomery Åsberg Depression Rating Scale (MADRS) Total Score at Each Week

    The MADRS is a depression rating scale consisting of 10 items, each rated 0 to 6. The 10 items represent the core symptoms of depressive illness. The overall score ranges from 0 (symptoms absent) to 60 (severe depression). A decrease in the total score or on individual items indicates improvement. LS means are from a mixed model for repeated measurements (MMRM) with Baseline-by-week, center, week, and week-by-treatment as factors in the analysis.

    Time frame: Baseline and Weeks 1, 2, 4, 6, and 8

  14. Change From Baseline in Hamilton Anxiety Scale (HAM-A) Total Score at Each Week Assessed

    The HAM-A is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total scores range from 0 to 56, where \<17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe. Total scores above 30 are rare, but indicate very severe anxiety. LS means are from a mixed model for repeated measurements (MMRM) with Baseline-by-week, center, week, and week-by-treatment as factors in the analysis.

    Time frame: Baseline and Weeks 1, 2, 4, 6, and 8

  15. Change From Baseline in Clinical Global Impression Scale-Severity of Illness at Each Week Assessed

    The Clinical Global Impression - Severity scale (CGI-S) is a 7-point scale that requires the clinician to rate the severity of the participant's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis. Considering total clinical experience, a patient is assessed on severity of mental illness on the following scale: 1, normal, not at all ill; 2, borderline mentally ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; or 7, extremely ill. LS means are from a mixed model for repeated measurements (MMRM) with Baseline-by-week, center, week, and week-by-treatment as factors in the analysis.

    Time frame: Baseline and Weeks 1, 2, 4, 6, and 8

  16. Change From Baseline in Hospital Anxiety and Depression (HAD) Scales at Each Week Assessed

    The HAD scale is completed by the participant and comprises two subscales, one measuring depression (focusing on the state of lost interest and diminished pleasure response) and one measuring anxiety (including anxious mood, restlessness, anxious thoughts, panic attacks). Each subscale is made up of 7 items that are assessed on a scale of 0 = no anxiety/depression to 3 = severe feeling of anxiety/depression. Participants are required to indicate the response which most accurately reflects the way they have felt over the last few days. Scores for the depression and anxiety subscales are summed separately and not combined, with each score ranging from 0 to 21 (maximal severity). LS means are from a mixed model for repeated measurements (MMRM) with Baseline-by-week, center, week, and week-by-treatment as factors in the analysis

    Time frame: Baseline and Weeks 1, 4, and 8

  17. Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Physical Functioning Subscore at All Weeks Assessed

    The Medical Outcomes Study SF-36 is a participant self-rated questionnaire that is a general measure of perceived health status comprising 36 questions, which yields an 8-scale health profile. The physical functioning subscale assesses limitations in physical activities because of health problems. The sub-score scale ranges from 0 (best) - 100 (worst). LS means are from a mixed model for repeated measurements (MMRM) with Baseline-by-week, center, week, and week-by-treatment as factors in the analysis.

    Time frame: Baseline and Weeks 2, 4 and 8

  18. Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Role-Physical Subscore at All Weeks Assessed

    The Medical Outcomes Study SF-36 is a participant self-rated questionnaire that is a general measure of perceived health status comprising 36 questions, which yields an 8-scale health profile. The role-physical subscale assesses limitations in usual role activities because of physical health problems. The sub-score scale ranges from 0 (best) - 100 (worst). LS means are from a mixed model for repeated measurements (MMRM) with Baseline-by-week, center, week, and week-by-treatment as factors in the analysis.

    Time frame: Baseline and Weeks 2, 4 and 8

  19. Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Bodily Pain Subscore at All Weeks Assessed

    The Medical Outcomes Study SF-36 is a participant self-rated questionnaire that is a general measure of perceived health status comprising 36 questions, which yields an 8-scale health profile. The bodily pain sub-score scale ranges from 0 (best) - 100 (worst). LS means are from a mixed model for repeated measurements (MMRM) with Baseline-by-week, center, week, and week-by-treatment as factors in the analysis.

    Time frame: Baseline and Weeks 2, 4 and 8

  20. Change From Baseline in 36-Item Short-Form Health Survey (SF-36) General Health Subscore at All Weeks Assessed

    The Medical Outcomes Study SF-36 is a participant self-rated questionnaire that is a general measure of perceived health status comprising 36 questions, which yields an 8-scale health profile. The general health sub-score scale ranges from 0 (best) - 100 (worst). LS means are from a mixed model for repeated measurements (MMRM) with Baseline-by-week, center, week, and week-by-treatment as factors in the analysis.

    Time frame: Baseline and Weeks 2, 4 and 8

  21. Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Vitality Subscore at All Weeks Assessed

    The Medical Outcomes Study SF-36 is a participant self-rated questionnaire that is a general measure of perceived health status comprising 36 questions, which yields an 8-scale health profile. The vitality sub-score assesses energy and fatigue, and ranges from 0 (best) - 100 (worst). LS means are from a mixed model for repeated measurements (MMRM) with Baseline-by-week, center, week, and week-by-treatment as factors in the analysis.

    Time frame: Baseline and Weeks 2, 4 and 8

  22. Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Social Functioning Subscore at Other Weeks Assessed

    The Medical Outcomes Study SF-36 is a participant self-rated questionnaire that is a general measure of perceived health status comprising 36 questions, which yields an 8-scale health profile. The social functioning subscale assesses limitations in social activities because of physical or emotional problems. The sub-score scale ranges from 0 (best) - 100 (worst). LS means are from a mixed model for repeated measurements (MMRM) with Baseline-by-week, center, week, and week-by-treatment as factors in the analysis.

    Time frame: Baseline and Weeks 2 and 4

  23. Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Role-Emotional Subscore at All Weeks Assessed

    The Medical Outcomes Study SF-36 is a participant self-rated questionnaire that is a general measure of perceived health status comprising 36 questions, which yields an 8-scale health profile. The role-emotional subscale assesses limitations in usual role activities because of emotional problems. The sub-score scale ranges from 0 (best) - 100 (worst). LS means are from a mixed model for repeated measurements (MMRM) with Baseline-by-week, center, week, and week-by-treatment as factors in the analysis.

    Time frame: Baseline and Weeks 2, 4 and 8

  24. Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Mental Health Subscore at All Weeks Assessed

    The Medical Outcomes Study SF-36 is a participant self-rated questionnaire that is a general measure of perceived health status comprising 36 questions, which yields an 8-scale health profile. The mental health sub-score assesses general mental health (psychological distress and well-being) and ranges from 0 (best) - 100 (worst). LS means are from a mixed model for repeated measurements (MMRM) with Baseline-by-week, center, week, and week-by-treatment as factors in the analysis.

    Time frame: Baseline and Weeks 2, 4 and 8

  25. Healthcare Resource Utilization as Assessed by the Health Economic Assessment Questionnaire.

    Healthcare resource utilization was assessed by the Health Economic Assessment (HEA) questionnaire, which monitors the participants' absenteeism from work, as well as resource use such as visits to a general practitioner, outpatient and inpatient services, hospitalization, medications, and other relevant services over the past 8 weeks.

    Time frame: Baseline and Week 8

07

Results

Posted Dec 18, 2013

Participant flow

Participants took part in the study at 51 investigative sites in Australia, Croatia, France, Germany, Latvia, Lithuania, Malaysia, Netherlands, Poland, Republic of Korea, Russia, South Africa, Taiwan, and Ukraine from 14 August 2008 to 13 August 2009.

Participant flow — Overall Study
MilestonePlaceboVortioxetine 1 mgVortioxetine 5 mgVortioxetine 10 mg
Started140140140140
Treated140140140139
Completed127127129122
Not completed13131118
Withdrew: Adverse event2315
Withdrew: Lack of efficacy8423
Withdrew: Noncompliance0010
Withdrew: Protocol deviations1211
Withdrew: Voluntary withdrawal1357
Withdrew: Lost to follow-up0111
Withdrew: Excluded medication1001

Outcome measures

PrimaryChange From Baseline in the 24-item Hamilton Depression Scale Total Score At Week 8

The 24-item Hamilton Depression Scale (HAM-D24) is a clinician-rated 24-item scale for assessing the severity of depression symptoms. The scores for each item range from 0 to 4 or 0 to 2, where 0 represents no symptoms. The rating is based on the past 7 days prior to the time of assessment. The total score range is from 0 to 74 where a higher score indicates a greater depressive state. Least squares (LS) means are from a mixed model for repeated measurements (MMRM) with Baseline-by-week, center, week, and week-by-treatment as factors in the analysis.

Time frame:
Baseline to Week 8
Reported as:
Least squares mean · scores on a scale
Change From Baseline in the 24-item Hamilton Depression Scale Total Score At Week 8
scores on a scalePlaceboVortioxetine 1 mgVortioxetine 5 mgVortioxetine 10 mg
Change From Baseline in the 24-item Hamilton Depression Scale Total Score At Week 8-11.30 ± 0.738-14.82 ± 0.745-15.42 ± 0.743-16.23 ± 0.755
Statistical analysis
  • Placebo vs Vortioxetine 10 mg · Mixed model for repeated measurements · p = <0.001 (Pre-specified sequential statistical testing procedure indicates that when p-value \<0.05, hierarchical testing continues.) · Ls mean difference: -4.93 · 95% CI -6.99 to -2.86P-values are from an MMRM model with Baseline-by-week, center, week, and week-by-treatment as factors in the analysis.
  • Placebo vs Vortioxetine 5 mg · Mixed model for repeated measurements · p = <0.001 (Hierarchical testing stopped at SDS total score at Week 8 in the testing sequence, a nominal p-value is provided.) · Ls mean difference: -4.12 · 95% CI -6.17 to -2.08P-values are from an MMRM model with Baseline-by-week, center, week, and week-by-treatment as factors in the analysis.
  • Placebo vs Vortioxetine 1 mg · Mixed model for repeated measurements · p = <0.001 (This treatment arm is not in the testing sequence, a nominal p-value is provided.) · Ls mean difference: -3.52 · 95% CI -5.57 to -1.47P-values are from an MMRM model with Baseline-by-week, center, week, and week-by-treatment as factors in the analysis.
SecondaryChange From Baseline in Sheehan Disability Scale (SDS) Total Score at Week 8

The Sheehan Disability Scale assesses functional impairment in 3 domains: work/school, social life or leisure activities, and home life or family responsibilities. The participant rates the extent to which each aspect is impaired on a 10-point visual analog scale, from 0 (not at all) to 10 (extremely). The 3 scores are added together to calculate the total score, which ranges from 0 to 30, with higher scores indicating more impairment. LS means are from a mixed model for repeated measurements (MMRM) with Baseline-by-week, center, week, and week-by-treatment as factors in the analysis.

Time frame:
Baseline to Week 8
Reported as:
Least squares mean · scores on a scale
Change From Baseline in Sheehan Disability Scale (SDS) Total Score at Week 8
scores on a scalePlaceboVortioxetine 1 mgVortioxetine 5 mgVortioxetine 10 mg
Change From Baseline in Sheehan Disability Scale (SDS) Total Score at Week 8-6.54 ± 0.716-6.58 ± 0.729-7.65 ± 0.713-8.08 ± 0.756
Statistical analysis
  • Placebo vs Vortioxetine 10 mg · Mixed model repeated measurements · p = 0.135 (Pre-specified sequential statistical testing procedure indicates that when p-value \>0.05, hierarchical testing stops and for subsequent endpoints in the sequence a nominal p-value is provided.) · Ls mean difference: -1.54 · 95% CI -3.56 to 0.48P-values are from an MMRM model with Baseline-by-week, center, week, and week-by-treatment as factors in the analysis.
  • Placebo vs Vortioxetine 5 mg · Mixed model repeated measurements · p = 0.263 · Ls mean difference: -1.11 · 95% CI -3.07 to 0.84P-values are from an MMRM model with Baseline-by-week, center, week, and week-by-treatment as factors in the analysis.
  • Placebo vs Vortioxetine 1 mg · Mixed model repeated measurements · p = 0.963 · Ls mean difference: -0.05 · 95% CI -2.03 to 1.94P-values are from an MMRM model with Baseline-by-week, center, week, and week-by-treatment as factors in the analysis.
SecondaryClinical Global Impression Scale-Global Improvement at Week 8

The Clinical Global Impression - Global Improvement scale assesses the participant's improvement (or worsening) as assessed by the clinician relative to Baseline on a 7-point scale: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse. LS means are from a mixed model for repeated measurements (MMRM) with Baseline-by-week, center, week, and week-by-treatment as factors in the analysis.

Time frame:
Baseline to Week 8
Reported as:
Least squares mean · scores on a scale
Clinical Global Impression Scale-Global Improvement at Week 8
scores on a scalePlaceboVortioxetine 1 mgVortioxetine 5 mgVortioxetine 10 mg
Clinical Global Impression Scale-Global Improvement at Week 82.84 ± 0.0892.37 ± 0.0902.37 ± 0.0892.29 ± 0.091
Statistical analysis
  • Placebo vs Vortioxetine 10 mg · Mixed model repeated measurements · p = <0.001 · Ls mean difference: -0.55 · 95% CI -0.80 to -0.30P-values are from an MMRM model with Baseline-by-week, center, week, and week-by-treatment as factors in the analysis.
  • Placebo vs Vortioxetine 5 mg · Mixed model repeated measurements · p = <0.001 · Ls mean difference: -0.47 · 95% CI -0.71 to -0.22P-values are from an MMRM model with Baseline-by-week, center, week, and week-by-treatment as factors in the analysis.
  • Placebo vs Vortioxetine 1 mg · Mixed model repeated measurements · p = <0.001 · Ls mean difference: -0.47 · 95% CI -0.72 to -0.23P-values are from an MMRM model with Baseline-by-week, center, week, and week-by-treatment as factors in the analysis.
SecondaryPercentage of Responders in HAM-D24 Total Score at Week 8

A responder is defined as a participant with a ≥50% decrease from Baseline in HAM-D24 total score. The HAM-D24 is a clinician-rated 24-item scale for assessing the severity of depression symptoms. The scores for each item range from 0 to 4 or 0 to 2, where 0 represents no symptoms. The rating is based on the past 7 days prior to the time of assessment. The total score ranges from 0 to 74, where a higher score indicates a greater depressive state.

Time frame:
Baseline and Week 8
Reported as:
Number · percentage of participants
Percentage of Responders in HAM-D24 Total Score at Week 8
percentage of participantsPlaceboVortioxetine 1 mgVortioxetine 5 mgVortioxetine 10 mg
Percentage of Responders in HAM-D24 Total Score at Week 823.047.545.349.6
Statistical analysis
  • Placebo vs Vortioxetine 10 mg · Regression, Logistic · p = <0.001 · Odds ratio (or): 3.348 · 95% CI 1.995 to 5.618Odds ratio versus placebo.
  • Placebo vs Vortioxetine 5 mg · Regression, Logistic · p = <0.001 · Odds ratio (or): 2.739 · 95% CI 1.631 to 4.598Odds ratio versus placebo
  • Placebo vs Vortioxetine 1 mg · Regression, Logistic · p = <0.001 · Odds ratio (or): 3.018 · 95% CI 1.799 to 5.063Odds ratio versus placebo
SecondaryChange From Baseline in HAM-D24 Total Score at Week 8 in Participants With Baseline HAM-A Score ≥20

The HAM-D24 is a clinician-rated 24-item scale for assessing the severity of depression symptoms. The scores for each item range from 0 to 4 or 0 to 2, where 0 represents no symptoms. The rating is based on the past 7 days prior to the time of assessment. The total score ranges from 0 to 74 where a higher score indicates a greater depressive state. The Hamilton Anxiety Scale (HAM-A) is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total scores range from 0 (symptoms absent) to 56 (severe symptoms). LS means are from a mixed model for repeated measurements (MMRM) with Baseline-by-week, center, week, and week-by-treatment as factors in the analysis.

Time frame:
Baseline to Week 8
Reported as:
Least squares mean · scores on a scale
Change From Baseline in HAM-D24 Total Score at Week 8 in Participants With Baseline HAM-A Score ≥20
scores on a scalePlaceboVortioxetine 1 mgVortioxetine 5 mgVortioxetine 10 mg
Change From Baseline in HAM-D24 Total Score at Week 8 in Participants With Baseline HAM-A Score ≥20-11.02 ± 1.017-15.16 ± 0.991-15.50 ± 1.063-15.61 ± 0.984
Statistical analysis
  • Placebo vs Vortioxetine 10 mg · Mixed model for repeated measurements · p = 0.001 · Ls mean difference: -4.59 · 95% CI -7.34 to -1.84P-values are from an MMRM model with Baseline-by-week, center, week, and week-by-treatment as factors in the analysis.
  • Placebo vs Vortioxetine 5 mg · Mixed model for repeated measurements · p = 0.002 · Ls mean difference: -4.47 · 95% CI -7.32 to -1.62P-values are from an MMRM model with Baseline-by-week, center, week, and week-by-treatment as factors in the analysis.
  • Placebo vs Vortioxetine 1 mg · Mixed model for repeated measurements · p = 0.004 · Ls mean difference: -4.13 · 95% CI -6.90 to -1.37P-values are from an MMRM model with Baseline-by-week, center, week, and week-by-treatment as factors in the analysis.
SecondaryPercentage of Participants in MADRS Remission at Week 8

Remission is defined as a participant with a Montgomery Åsberg Depression Rating Scale (MADRS) total score ≤10. The MADRS is a depression rating scale consisting of 10 items, each rated 0 to 6. The 10 items represent the core symptoms of depressive illness. The overall score ranges from 0 (symptoms absent) to 60 (severe depression). Decrease in the total score or on individual items indicates improvement.

Time frame:
Week 8
Reported as:
Number · percentage of participants
Percentage of Participants in MADRS Remission at Week 8
percentage of participantsPlaceboVortioxetine 1 mgVortioxetine 5 mgVortioxetine 10 mg
Percentage of Participants in MADRS Remission at Week 816.525.928.826.6
Statistical analysis
  • Placebo vs Vortioxetine 10 mg · Regression, Logistic · p = 0.026 · Odds ratio (or): 1.951 · 95% CI 1.082 to 3.517Logistic regression with explanatory variables for treatment and Baseline MADRS score.
  • Placebo vs Vortioxetine 5 mg · Regression, Logistic · p = 0.015 · Odds ratio (or): 2.056 · 95% CI 1.150 to 3.673Logistic regression with explanatory variables for treatment and Baseline MADRS score.
  • Placebo vs Vortioxetine 1 mg · Regression, Logistic · p = 0.062 · Odds ratio (or): 1.753 · 95% CI 0.973 to 3.158Logistic regression with explanatory variables for treatment and Baseline MADRS score.
SecondaryChange From Baseline in the 24-item Hamilton Depression Scale Total Score at Other Weeks Assessed

The HAM-D24 is a clinician-rated 24-item scale for assessing the severity of depression symptoms. The scores for each item range from 0 to 4 or 0 to 2, where 0 represents no symptoms. The rating is based on the past 7 days prior to the time of assessment. The total score range is from 0 to 74 where a higher score indicates a greater depressive state. LS means are from a mixed model for repeated measurements (MMRM) with Baseline-by-week, center, week, and week-by-treatment as factors in the analysis.

Time frame:
Baseline and Weeks 1, 2, 4 and 6
Reported as:
Least squares mean · scores on a scale
Change From Baseline in the 24-item Hamilton Depression Scale Total Score at Other Weeks Assessed
scores on a scalePlaceboVortioxetine 1 mgVortioxetine 5 mgVortioxetine 10 mg
Week 1 (n=139, 137, 138, 138)-3.47 ± 0.321-2.81 ± 0.323-3.20 ± 0.322-3.20 ± 0.321
Week 2 (n=138, 138, 135, 135)-5.66 ± 0.485-7.27 ± 0.485-7.27 ± 0.490-7.42 ± 0.489
Week 4 (n=135, 133, 135, 127)-8.42 ± 0.634-11.09 ± 0.637-11.00 ± 0.639-11.88 ± 0.646
Week 6 (n=134, 130, 129, 126)-10.23 ± 0.690-13.35 ± 0.695-13.67 ± 0.697-15.22 ± 0.705
SecondaryChange From Baseline in Sheehan Disability Scale (SDS) Total Score at Other Weeks Assessed

The Sheehan Disability Scale assesses functional impairment in 3 domains: work/school, social life or leisure activities, and home life or family responsibilities. The participant rates the extent to which each aspect is impaired on a 10-point visual analog scale, from 0 (not at all) to 10 (extremely). The 3 scores are added together to calculate the total score, which ranges from 0 to 30, with higher scores indicating more impairment. LS means are from a mixed model for repeated measurements (MMRM) with Baseline-by-week, center, week, and week-by-treatment as factors in the analysis.

Time frame:
Baseline and Weeks 1, 2 and 6
Reported as:
Least squares mean · scores on a scale
Change From Baseline in Sheehan Disability Scale (SDS) Total Score at Other Weeks Assessed
scores on a scalePlaceboVortioxetine 1 mgVortioxetine 5 mgVortioxetine 10 mg
Week 1 (n=104, 101, 105, 97)-1.22 ± 0.392-1.13 ± 0.399-1.78 ± 0.393-1.43 ± 0.403
Week 2 (n=102, 101, 100, 96)-2.53 ± 0.507-3.44 ± 0.511-4.14 ± 0.512-3.40 ± 0.521
Week 6 (n=99, 97, 97, 88)-5.95 ± 0.672-5.69 ± 0.681-6.92 ± 0.678-8.27 ± 0.707
SecondaryClinical Global Impression Scale-Global Improvement at Other Weeks Assessed

The Clinical Global Impression - global improvement assesses the participant's improvement (or worsening) as assessed by the clinician relative to Baseline on a 7-point scale: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse. LS means are from a mixed model for repeated measurements (MMRM) with Baseline-by-week, center, week, and week-by-treatment as factors in the analysis.

Time frame:
Baseline and Weeks 1, 2, 4 and 6
Reported as:
Least squares mean · scores on a scale
Clinical Global Impression Scale-Global Improvement at Other Weeks Assessed
scores on a scalePlaceboVortioxetine 1 mgVortioxetine 5 mgVortioxetine 10 mg
Week 1 (n=139, 137, 138, 138)3.65 ± 0.0533.71 ± 0.0543.67 ± 0.0533.64 ± 0.053
Week 2 (n=138, 138, 135, 135)3.40 ± 0.0693.16 ± 0.0703.19 ± 0.0703.23 ± 0.070
Week 4 (n=135, 133, 135, 127)3.03 ± 0.0822.69 ± 0.0832.82 ± 0.0832.78 ± 0.084
Week 6 (n=134, 130, 129, 126)2.95 ± 0.0872.48 ± 0.0882.50 ± 0.0882.37 ± 0.089
SecondaryPercentage of Responders in HAM-D24 Total Score at Other Weeks Assessed

A responder is defined as a participant with a ≥50% decrease from Baseline in HAM-D24 total score. The HAM-D24 is a clinician-rated 24-item scale for assessing the severity of depression symptoms. The scores for each item range from 0 to 4 or 0 to 2, where 0 represents no symptoms. The rating is based on the past 7 days prior to the time of assessment. The total score ranges from 0 to 74, where a higher score indicates a greater depressive state.

Time frame:
Baseline and Weeks 1, 2, 4 and 6
Reported as:
Number · percentage of participants
Percentage of Responders in HAM-D24 Total Score at Other Weeks Assessed
percentage of participantsPlaceboVortioxetine 1 mgVortioxetine 5 mgVortioxetine 10 mg
Week 1 (n=139, 137, 138, 138)0.70.70.71.4
Week 2 (n=139, 139, 139, 139)5.07.97.28.6
Week 4 (n=139, 139, 139, 139)18.027.324.526.6
Week 6 (n=139, 139, 139, 139)23.738.136.043.9
SecondaryChange From Baseline in HAM-D24 Total Score at Other Weeks Assessed in Participants With a Baseline HAM-A Score ≥20

The HAM-D24 is a clinician-rated 24-item scale for assessing the severity of depression symptoms. The scores for each item range from 0 to 4 or 0 to 2, where 0 represents no symptoms. The rating is based on the past 7 days prior to the time of assessment. The total score range from 0 to 74 where a higher score indicates a greater depressive state. The Hamilton Anxiety Scale (HAM-A) is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total scores range from 0 (symptoms absent) to 56 (symptoms severe). LS means are from a mixed model for repeated measurements (MMRM) with Baseline-by-week, center, week, and week-by-treatment as factors in the analysis.

Time frame:
Baseline and Weeks 1, 2, 4 and 6
Reported as:
Least squares mean · scores on a scale
Change From Baseline in HAM-D24 Total Score at Other Weeks Assessed in Participants With a Baseline HAM-A Score ≥20
scores on a scalePlaceboVortioxetine 1 mgVortioxetine 5 mgVortioxetine 10 mg
Week 1 (n=66, 70, 62, 75)-3.79 ± 0.473-2.94 ± 0.463-3.55 ± 0.491-3.19 ± 0.447
Week 2 (n=65, 70, 59, 72)-5.76 ± 0.637-7.21 ± 0.618-6.58 ± 0.667-7.74 ± 0.607
Week 4 (n=64, 68, 60, 69)-8.56 ± 0.874-11.41 ± 0.850-10.20 ± 0.910-12.06 ± 0.841
Week 6 (n=64, 67, 57, 68)-10.25 ± 0.958-13.68 ± 0.932-13.23 ± 1.002-15.10 ± 0.923
SecondaryPercentage of Participants in MADRS Remission at Other Weeks Assessed

Remission is defined as a participant with a Montgomery Åsberg Depression Rating Scale (MADRS) total score ≤10. The MADRS is a depression rating scale consisting of 10 items, each rated 0 to 6. The 10 items represent the core symptoms of depressive illness. The overall score ranges from 0 (symptoms absent) to 60 (severe depression). Decrease in the total score or on individual items indicates improvement.

Time frame:
Weeks 1, 2, 4 and 6
Reported as:
Number · percentage of participants
Percentage of Participants in MADRS Remission at Other Weeks Assessed
percentage of participantsPlaceboVortioxetine 1 mgVortioxetine 5 mgVortioxetine 10 mg
Week 1 (n=139, 137, 138, 138)0.70.700
Week 2 (n=139, 139, 139, 139)2.22.21.41.4
Week 4 (n=139, 139, 139, 139)6.511.511.510.8
Week 6 (n=139, 139, 139, 139)10.120.120.922.3
SecondaryPercentage of Participants With a Sustained Response in HAM-D24 Total Score

A sustained response is defined as a ≥20% decrease from Baseline in HAM-D24 total score obtained at Week 1 and sustained through Week 7 and at least 50% decrease from Baseline at Week 8.

Time frame:
From Baseline through Week 8
Reported as:
Number · percentage of participants
Percentage of Participants With a Sustained Response in HAM-D24 Total Score
percentage of participantsPlaceboVortioxetine 1 mgVortioxetine 5 mgVortioxetine 10 mg
Percentage of Participants With a Sustained Response in HAM-D24 Total Score10.19.410.110.8
SecondaryChange From Baseline in Montgomery Åsberg Depression Rating Scale (MADRS) Total Score at Each Week

The MADRS is a depression rating scale consisting of 10 items, each rated 0 to 6. The 10 items represent the core symptoms of depressive illness. The overall score ranges from 0 (symptoms absent) to 60 (severe depression). A decrease in the total score or on individual items indicates improvement. LS means are from a mixed model for repeated measurements (MMRM) with Baseline-by-week, center, week, and week-by-treatment as factors in the analysis.

Time frame:
Baseline and Weeks 1, 2, 4, 6, and 8
Reported as:
Least squares mean · scores on a scale
Change From Baseline in Montgomery Åsberg Depression Rating Scale (MADRS) Total Score at Each Week
scores on a scalePlaceboVortioxetine 1 mgVortioxetine 5 mgVortioxetine 10 mg
Week 1 (n=139, 137, 138, 138)-2.90 ± 0.324-2.55 ± 0.326-2.66 ± 0.324-2.57 ± 0.328
Week 2 (n=138, 138, 135, 135)-4.92 ± 0.463-6.65 ± 0.463-6.40 ± 0.467-6.51 ± 0.472
Week 4 (n=135, 133, 135, 127)-7.85 ± 0.619-10.79 ± 0.622-10.30 ± 0.622-10.89 ± 0.635
Week 6 (n=134, 130, 129, 126)-9.72 ± 0.675-13.16 ± 0.680-13.10 ± 0.680-14.19 ± 0.694
Week 8 (n=128, 124, 129, 122)-10.91 ± 0.708-14.89 ± 0.715-15.09 ± 0.712-15.65 ± 0.728
SecondaryChange From Baseline in Hamilton Anxiety Scale (HAM-A) Total Score at Each Week Assessed

The HAM-A is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total scores range from 0 to 56, where \<17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe. Total scores above 30 are rare, but indicate very severe anxiety. LS means are from a mixed model for repeated measurements (MMRM) with Baseline-by-week, center, week, and week-by-treatment as factors in the analysis.

Time frame:
Baseline and Weeks 1, 2, 4, 6, and 8
Reported as:
Least squares mean · scores on a scale
Change From Baseline in Hamilton Anxiety Scale (HAM-A) Total Score at Each Week Assessed
scores on a scalePlaceboVortioxetine 1 mgVortioxetine 5 mgVortioxetine 10 mg
Week 1 (n=139, 137, 138, 138)-1.58 ± 0.260-1.27 ± 0.261-1.41 ± 0.261-1.56 ± 0.261
Week 2 (n=138, 138, 135, 135)-3.06 ± 0.343-3.72 ± 0.343-3.09 ± 0.346-3.77 ± 0.347
Week 4 (n=135, 133, 135, 127)-4.54 ± 0.416-5.95 ± 0.418-5.60 ± 0.418-6.11 ± 0.425
Week 6 (n=134, 130, 129, 126)-5.44 ± 0.471-7.29 ± 0.475-7.21 ± 0.476-8.33 ± 0.483
Week 8 (n=128, 124, 129, 122)-5.98 ± 0.498-8.08 ± 0.503-8.11 ± 0.501-8.86 ± 0.511
SecondaryChange From Baseline in Clinical Global Impression Scale-Severity of Illness at Each Week Assessed

The Clinical Global Impression - Severity scale (CGI-S) is a 7-point scale that requires the clinician to rate the severity of the participant's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis. Considering total clinical experience, a patient is assessed on severity of mental illness on the following scale: 1, normal, not at all ill; 2, borderline mentally ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; or 7, extremely ill. LS means are from a mixed model for repeated measurements (MMRM) with Baseline-by-week, center, week, and week-by-treatment as factors in the analysis.

Time frame:
Baseline and Weeks 1, 2, 4, 6, and 8
Reported as:
Least squares mean · scores on a scale
Change From Baseline in Clinical Global Impression Scale-Severity of Illness at Each Week Assessed
scores on a scalePlaceboVortioxetine 1 mgVortioxetine 5 mgVortioxetine 10 mg
Week 1 (n=139, 137, 138, 138)-0.24 ± 0.044-0.20 ± 0.045-0.22 ± 0.044-0.24 ± 0.044
Week 2 (n=138, 138, 135, 135)-0.46 ± 0.062-0.58 ± 0.062-0.61 ± 0.062-0.60 ± 0.062
Week 4 (n=135, 133, 135, 127)-0.75 ± 0.080-1.07 ± 0.081-1.10 ± 0.081-1.06 ± 0.082
Week 6 (n=134, 130, 129, 126)-0.96 ± 0.092-1.41 ± 0.093-1.38 ± 0.093-1.55 ± 0.094
Week 8 (n=128, 124, 129, 122)-1.12 ± 0.101-1.50 ± 0.102-1.63 ± 0.101-1.74 ± 0.103
SecondaryChange From Baseline in Hospital Anxiety and Depression (HAD) Scales at Each Week Assessed

The HAD scale is completed by the participant and comprises two subscales, one measuring depression (focusing on the state of lost interest and diminished pleasure response) and one measuring anxiety (including anxious mood, restlessness, anxious thoughts, panic attacks). Each subscale is made up of 7 items that are assessed on a scale of 0 = no anxiety/depression to 3 = severe feeling of anxiety/depression. Participants are required to indicate the response which most accurately reflects the way they have felt over the last few days. Scores for the depression and anxiety subscales are summed separately and not combined, with each score ranging from 0 to 21 (maximal severity). LS means are from a mixed model for repeated measurements (MMRM) with Baseline-by-week, center, week, and week-by-treatment as factors in the analysis

Time frame:
Baseline and Weeks 1, 4, and 8
Reported as:
Least squares mean · scores on a scale
Change From Baseline in Hospital Anxiety and Depression (HAD) Scales at Each Week Assessed
scores on a scalePlaceboVortioxetine 1 mgVortioxetine 5 mgVortioxetine 10 mg
Anxiety Scale at Week 1 (n=139, 137, 138, 137)-0.46 ± 0.190-1.14 ± 0.190-0.87 ± 0.189-0.91 ± 0.190
Anxiety Scale at Week 4 (n=137, 138, 135, 134)-1.95 ± 0.277-2.83 ± 0.276-2.81 ± 0.278-2.80 ± 0.279
Anxiety Scale at Week 8 (n=129, 129, 127, 122)-2.55 ± 0.315-3.79 ± 0.315-3.70 ± 0.317-4.38 ± 0.321
Depression Scale at Week 1 (n=139, 137, 138, 137)-0.32 ± 0.217-0.90 ± 0.217-0.74 ± 0.216-0.92 ± 0.218
Depression Scale at Week 4 (n=137, 138, 135, 134)-2.32 ± 0.348-3.45 ± 0.347-3.32 ± 0.350-3.80 ± 0.352
Depression Scale at Week 8 (n=129, 129, 127, 122)-3.19 ± 0.392-4.67 ± 0.393-5.02 ± 0.396-5.49 ± 0.401
SecondaryChange From Baseline in 36-Item Short-Form Health Survey (SF-36) Physical Functioning Subscore at All Weeks Assessed

The Medical Outcomes Study SF-36 is a participant self-rated questionnaire that is a general measure of perceived health status comprising 36 questions, which yields an 8-scale health profile. The physical functioning subscale assesses limitations in physical activities because of health problems. The sub-score scale ranges from 0 (best) - 100 (worst). LS means are from a mixed model for repeated measurements (MMRM) with Baseline-by-week, center, week, and week-by-treatment as factors in the analysis.

Time frame:
Baseline and Weeks 2, 4 and 8
Reported as:
Least squares mean · scores on a scale
Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Physical Functioning Subscore at All Weeks Assessed
scores on a scalePlaceboVortioxetine 1 mgVortioxetine 5 mgVortioxetine 10 mg
Week 2 (n=138,139,136,136)2.24 ± 1.2795.39 ± 1.2737.55 ± 1.2853.34 ± 1.289
Week 4 (n=135,132,135,128)5.10 ± 1.3547.77 ± 1.3649.35 ± 1.3566.92 ± 1.385
Week 8 (n=129,129,128,122)8.77 ± 1.4079.59 ± 1.40812.31 ± 1.41111.28 ± 1.441
SecondaryChange From Baseline in 36-Item Short-Form Health Survey (SF-36) Role-Physical Subscore at All Weeks Assessed

The Medical Outcomes Study SF-36 is a participant self-rated questionnaire that is a general measure of perceived health status comprising 36 questions, which yields an 8-scale health profile. The role-physical subscale assesses limitations in usual role activities because of physical health problems. The sub-score scale ranges from 0 (best) - 100 (worst). LS means are from a mixed model for repeated measurements (MMRM) with Baseline-by-week, center, week, and week-by-treatment as factors in the analysis.

Time frame:
Baseline and Weeks 2, 4 and 8
Reported as:
Least squares mean · scores on a scale
Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Role-Physical Subscore at All Weeks Assessed
scores on a scalePlaceboVortioxetine 1 mgVortioxetine 5 mgVortioxetine 10 mg
Week 2 (n=138, 139, 136, 136)0.74 ± 1.5116.09 ± 1.5057.38 ± 1.5205.00 ± 1.525
Week 4 (n=135, 132, 135, 128)4.53 ± 1.70610.62 ± 1.72112.97 ± 1.7098.28 ± 1.748
Week 8 (n=129, 129, 128, 122)8.46 ± 1.83014.09 ± 1.83315.64 ± 1.83515.76 ± 1.878
SecondaryChange From Baseline in 36-Item Short-Form Health Survey (SF-36) Bodily Pain Subscore at All Weeks Assessed

The Medical Outcomes Study SF-36 is a participant self-rated questionnaire that is a general measure of perceived health status comprising 36 questions, which yields an 8-scale health profile. The bodily pain sub-score scale ranges from 0 (best) - 100 (worst). LS means are from a mixed model for repeated measurements (MMRM) with Baseline-by-week, center, week, and week-by-treatment as factors in the analysis.

Time frame:
Baseline and Weeks 2, 4 and 8
Reported as:
Least squares mean · scores on a scale
Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Bodily Pain Subscore at All Weeks Assessed
scores on a scalePlaceboVortioxetine 1 mgVortioxetine 5 mgVortioxetine 10 mg
Week 2 (n=138, 139, 136, 136)2.99 ± 1.6305.06 ± 1.6244.52 ± 1.6447.22 ± 1.644
Week 4 (n=135, 132, 135, 128)4.45 ± 1.7385.33 ± 1.7527.75 ± 1.74410.66 ± 1.778
Week 8 (n=129, 129, 128, 122)7.17 ± 1.92011.99 ± 1.9209.63 ± 1.92812.89 ± 1.970
SecondaryChange From Baseline in 36-Item Short-Form Health Survey (SF-36) General Health Subscore at All Weeks Assessed

The Medical Outcomes Study SF-36 is a participant self-rated questionnaire that is a general measure of perceived health status comprising 36 questions, which yields an 8-scale health profile. The general health sub-score scale ranges from 0 (best) - 100 (worst). LS means are from a mixed model for repeated measurements (MMRM) with Baseline-by-week, center, week, and week-by-treatment as factors in the analysis.

Time frame:
Baseline and Weeks 2, 4 and 8
Reported as:
Least squares mean · scores on a scale
Change From Baseline in 36-Item Short-Form Health Survey (SF-36) General Health Subscore at All Weeks Assessed
scores on a scalePlaceboVortioxetine 1 mgVortioxetine 5 mgVortioxetine 10 mg
Week 2 (n=138, 139, 136, 136)2.83 ± 1.0485.54 ± 1.0445.64 ± 1.0545.47 ± 1.056
Week 4 (n=135, 132, 135, 128)6.51 ± 1.2358.98 ± 1.2459.96 ± 1.23810.99 ± 1.263
Week 8 (n=129, 129, 128, 121)8.68 ± 1.39212.46 ± 1.39513.67 ± 1.39613.87 ± 1.429
SecondaryChange From Baseline in 36-Item Short-Form Health Survey (SF-36) Vitality Subscore at All Weeks Assessed

The Medical Outcomes Study SF-36 is a participant self-rated questionnaire that is a general measure of perceived health status comprising 36 questions, which yields an 8-scale health profile. The vitality sub-score assesses energy and fatigue, and ranges from 0 (best) - 100 (worst). LS means are from a mixed model for repeated measurements (MMRM) with Baseline-by-week, center, week, and week-by-treatment as factors in the analysis.

Time frame:
Baseline and Weeks 2, 4 and 8
Reported as:
Least squares mean · scores on a scale
Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Vitality Subscore at All Weeks Assessed
scores on a scalePlaceboVortioxetine 1 mgVortioxetine 5 mgVortioxetine 10 mg
Week 2 (n=138, 139, 136, 136)5.97 ± 1.19910.39 ± 1.1938.83 ± 1.2058.03 ± 1.208
Week 4 (n=135, 132, 135, 128)12.06 ± 1.52316.69 ± 1.53616.04 ± 1.52616.07 ± 1.560
Week 8 (n=129, 129, 128, 122)16.14 ± 1.74822.34 ± 1.75221.21 ± 1.75324.17 ± 1.793
SecondaryChange From Baseline in 36-Item Short-Form Health Survey (SF-36) Social Functioning Subscore at Other Weeks Assessed

The Medical Outcomes Study SF-36 is a participant self-rated questionnaire that is a general measure of perceived health status comprising 36 questions, which yields an 8-scale health profile. The social functioning subscale assesses limitations in social activities because of physical or emotional problems. The sub-score scale ranges from 0 (best) - 100 (worst). LS means are from a mixed model for repeated measurements (MMRM) with Baseline-by-week, center, week, and week-by-treatment as factors in the analysis.

Time frame:
Baseline and Weeks 2 and 4
Reported as:
Least squares mean · scores on a scale
Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Social Functioning Subscore at Other Weeks Assessed
scores on a scalePlaceboVortioxetine 1 mgVortioxetine 5 mgVortioxetine 10 mg
Week 2 (n=138, 139, 136, 136)6.38 ± 1.4799.71 ± 1.47312.02 ± 1.48610.03 ± 1.491
Week 4 (n=135, 132, 135, 128)12.34 ± 1.76015.71 ± 1.77518.57 ± 1.76215.84 ± 1.804
Week 8 (n=129, 129, 128, 122)15.60 ± 1.98921.71 ± 1.99121.87 ± 1.99324.94 ± 2.040
SecondaryChange From Baseline in 36-Item Short-Form Health Survey (SF-36) Role-Emotional Subscore at All Weeks Assessed

The Medical Outcomes Study SF-36 is a participant self-rated questionnaire that is a general measure of perceived health status comprising 36 questions, which yields an 8-scale health profile. The role-emotional subscale assesses limitations in usual role activities because of emotional problems. The sub-score scale ranges from 0 (best) - 100 (worst). LS means are from a mixed model for repeated measurements (MMRM) with Baseline-by-week, center, week, and week-by-treatment as factors in the analysis.

Time frame:
Baseline and Weeks 2, 4 and 8
Reported as:
Least squares mean · scores on a scale
Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Role-Emotional Subscore at All Weeks Assessed
scores on a scalePlaceboVortioxetine 1 mgVortioxetine 5 mgVortioxetine 10 mg
Week 2 (n=138, 139, 136, 136)6.84 ± 1.5708.78 ± 1.56310.87 ± 1.5799.93 ± 1.581
Week 4 (n=135, 132, 135, 128)12.05 ± 1.75517.01 ± 1.77218.08 ± 1.75814.58 ± 1.797
Week 8 (n=129, 129, 128, 122)15.96 ± 1.94123.06 ± 1.94622.89 ± 1.94724.71 ± 1.990
SecondaryChange From Baseline in 36-Item Short-Form Health Survey (SF-36) Mental Health Subscore at All Weeks Assessed

The Medical Outcomes Study SF-36 is a participant self-rated questionnaire that is a general measure of perceived health status comprising 36 questions, which yields an 8-scale health profile. The mental health sub-score assesses general mental health (psychological distress and well-being) and ranges from 0 (best) - 100 (worst). LS means are from a mixed model for repeated measurements (MMRM) with Baseline-by-week, center, week, and week-by-treatment as factors in the analysis.

Time frame:
Baseline and Weeks 2, 4 and 8
Reported as:
Least squares mean · scores on a scale
Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Mental Health Subscore at All Weeks Assessed
scores on a scalePlaceboVortioxetine 1 mgVortioxetine 5 mgVortioxetine 10 mg
Week 2 (n=138, 139, 136, 136)6.98 ± 1.19910.62 ± 1.1929.56 ± 1.20510.26 ± 1.207
Week 4 (n= 135, 132, 135, 128)13.06 ± 1.41816.78 ± 1.42916.56 ± 1.42116.38 ± 1.451
Week 8 (n=129, 129, 128, 122)16.28 ± 1.62523.61 ± 1.62822.24 ± 1.63124.89 ± 1.667
SecondaryHealthcare Resource Utilization as Assessed by the Health Economic Assessment Questionnaire.

Healthcare resource utilization was assessed by the Health Economic Assessment (HEA) questionnaire, which monitors the participants' absenteeism from work, as well as resource use such as visits to a general practitioner, outpatient and inpatient services, hospitalization, medications, and other relevant services over the past 8 weeks.

Time frame:
Baseline and Week 8
Reported as:
Number · participants
Healthcare Resource Utilization as Assessed by the Health Economic Assessment Questionnaire.
participantsPlaceboVortioxetine 1 mgVortioxetine 5 mgVortioxetine 10 mg
Baseline: Any resource use62647161
Baseline: Any hospitalization-related services4364
Baseline: Hospitalization related to depression3342
Baseline: Any sick leave1771421
Baseline: Sick leave related to depression1261018
Week 8: Any resource use31132525
Week 8: Any hospitalization-related service3012
Week 8: Hospitalization related to depression0010
Week 8: Any sick leave1661118
Week 8: Sick leave related to depression136914

Adverse events

Collected over Treatment-emergent adverse events are defined as adverse events whose onset occurred or intensity increased after the first dose of double-blind study drug through 30 days after permanent discontinuation of double-blind study drug.. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—2/140 (1.4%)39/140 (27.9%)
Vortioxetine 1 mg—1/140 (0.7%)36/140 (25.7%)
Vortioxetine 5 mg—1/140 (0.7%)56/140 (40%)
Vortioxetine 10 mg—2/139 (1.4%)39/139 (28.1%)
Most frequent serious events
Most frequent serious events
EventPlaceboVortioxetine 1 mgVortioxetine 5 mgVortioxetine 10 mg
PancreatitisGastrointestinal disorders1/1400/1400/1401/139
Suicide attemptPsychiatric disorders0/1400/1400/1401/139
TachycardiaCardiac disorders0/1400/1401/1400/139
DizzinessNervous system disorders1/1400/1400/1400/139
Hypertensive crisisVascular disorders0/1401/1400/1400/139
Most frequent other events
Showing 10 of 18
Most frequent other events
EventPlaceboVortioxetine 1 mgVortioxetine 5 mgVortioxetine 10 mg
NauseaGastrointestinal disorders6/14011/14022/14018/139
HeadacheNervous system disorders11/1409/14016/1407/139
DizzinessNervous system disorders3/1401/1405/1409/139
NasopharyngitisInfections and infestations8/1405/1407/1403/139
Abdominal pain upperGastrointestinal disorders5/1402/1401/1401/139
FatigueGeneral disorders0/1403/1405/1401/139
InfluenzaInfections and infestations2/1402/1405/1402/139
Back painMusculoskeletal and connective tissue disorders5/1402/1403/1401/139
DiarrhoeaGastrointestinal disorders2/1402/1403/1404/139
VertigoEar and labyrinth disorders1/1403/1404/1403/139

Baseline characteristics

Age Continuous
Age Continuous(years)PlaceboVortioxetine 1 mgVortioxetine 5 mgVortioxetine 10 mgTotal
Mean46.4 ± 12.2645.4 ± 11.8947.3 ± 11.9546.4 ± 12.2746.4 ± 12.08
Age, Customized
Age, Customized(participants)PlaceboVortioxetine 1 mgVortioxetine 5 mgVortioxetine 10 mgTotal
≤55 years103110102107422
>55 years37303833138
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboVortioxetine 1 mgVortioxetine 5 mgVortioxetine 10 mgTotal
Female86938785351
Male54475355209
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)PlaceboVortioxetine 1 mgVortioxetine 5 mgVortioxetine 10 mgTotal
Caucasian120129120114483
Black512210
Asian148172362
Other12115
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)PlaceboVortioxetine 1 mgVortioxetine 5 mgVortioxetine 10 mgTotal
Hispanic/Latino30014
Non-Hispanic/Non-Latino137140140139556
Region of Enrollment
Region of Enrollment(participants)PlaceboVortioxetine 1 mgVortioxetine 5 mgVortioxetine 10 mgTotal
Australia03014
Croatia255113
France521513
Germany63506456233
Latvia589527
Lithuania442313
Malaysia736622
Netherlands03317
Poland2016151162
Republic of Korea7591435
Russia122092061
South Africa565319
Taiwan00134
Ukraine1015111147
Weight
Weight(kg)PlaceboVortioxetine 1 mgVortioxetine 5 mgVortioxetine 10 mgTotal
Mean75.18 ± 14.92475.63 ± 17.27675.41 ± 17.02274.58 ± 15.19075.20 ± 16.099
Height
Height(cm)PlaceboVortioxetine 1 mgVortioxetine 5 mgVortioxetine 10 mgTotal
Mean168.70 ± 8.907168.56 ± 8.264168.56 ± 9.126168.70 ± 10.209168.63 ± 9.129

9 further baseline measures are reported on the registry.

08

Study locations

50 sites
  • Elizabeth Vale, Australia
  • Southport, Australia
  • Litomerice, Czech Republic
  • Lnare, Czech Republic
  • Prague, Czech Republic
  • Praha, Czech Republic
  • Bully les Mines, France
  • Marseille, France
  • Strasbourg, France
  • Bochum, Germany
  • Chemnitz, Germany
  • Dillingen, Germany
  • Huettenberg, Germany
  • Leipzig, Germany
  • Munchen, Germany
  • München, Germany
  • Nuernberg, Germany
  • Osnabrueck, Germany
  • Rodgau, Germany
  • Westerstede, Germany
  • Bucheon-si, Korea, Republic of
  • Namdong-gu, Korea, Republic of
  • Seoul, Korea, Republic of
  • Leipaja, Latvia
  • Riga, Latvia
  • Sigulda, Latvia
  • Strenci, Latvia
  • Vilnius, Lithuania
  • Kuala Lumpur, Malaysia
  • Wildervank, Netherlands
  • Białystok, Poland
  • Leszno, Poland
  • Skórzewo, Poland
  • Toruń, Poland
  • Tuszyn, Poland
  • Moscow, Russian Federation
  • Novgorod, Russian Federation
  • St. Petersburg, Russian Federation
  • Stavropol, Russian Federation
  • Tomsk, Russian Federation
  • Durban, South Africa
  • Noordheuwel, South Africa
  • Pretoria, South Africa
  • Lin-Yan District, Taiwan
  • Dnepropetrovsk, Ukraine
  • Kharkiv, Ukraine
  • Lugansk, Ukraine
  • Simferopol, Ukraine
  • Bath, United Kingdom
  • Bolton, United Kingdom
09

References and documents

Publications

  • Henigsberg N, Mahableshwarkar AR, Jacobsen P, Chen Y, Thase ME. A randomized, double-blind, placebo-controlled 8-week trial of the efficacy and tolerability of multiple doses of Lu AA21004 in adults with major depressive disorder. J Clin Psychiatry. 2012 Jul;73(7):953-9. doi: 10.4088/JCP.11m07470. PubMed 22901346 ↗
  • McIntyre RS, Florea I, Tonnoir B, Loft H, Lam RW, Christensen MC. Efficacy of Vortioxetine on Cognitive Functioning in Working Patients With Major Depressive Disorder. J Clin Psychiatry. 2017 Jan;78(1):115-121. doi: 10.4088/JCP.16m10744. PubMed 27780334 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2008, a primary completion of Jul 2009 and a completion of Aug 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2013, 4 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2008
First posted
Aug 15, 2008
Start
Aug 2008
Primary completionActual
Jul 2009
CompletionActual
Aug 2009
Results first posted
Dec 18, 2013
Last update
Dec 18, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 18, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00735709
Lead sponsor
Takeda
Collaborators
H. Lundbeck A/S
Responsible party
Sponsor
First posted
Aug 15, 2008
Start date
Aug 2008
Primary completion
Jul 2009
Completion
Aug 2009
Results posted
Dec 18, 2013
Last update
Dec 18, 2013

Study contacts

Medical Director Clinical Science
study director · Takeda

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vortioxetine

Start the discussion